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Background
Most randomized trials of treatment for asthma study highly selected patients under 
idealized conditions.
Methods
We conducted two parallel, multicenter, pragmatic trials to evaluate the real-world 
effectiveness of a leukotriene-receptor antagonist (LTRA) as compared with either an 
inhaled glucocorticoid for first-line asthma-controller therapy or a long-acting beta2-
agonist (LABA) as add-on therapy in patients already receiving inhaled glucocorticoid 
therapy. Eligible primary care patients 12 to 80 years of age had impaired asthma-
related quality of life (Mini Asthma Quality of Life Questionnaire [MiniAQLQ] score 
≤6) or inadequate asthma control (Asthma Control Questionnaire [ACQ] score ≥1). 
We randomly assigned patients to 2 years of open-label therapy, under the care of 
their usual physician, with LTRA (148 patients) or an inhaled glucocorticoid (158 
patients) in the first-line controller therapy trial and LTRA (170 patients) or LABA 
(182 patients) added to an inhaled glucocorticoid in the add-on therapy trial.
Results
Mean MiniAQLQ scores increased by 0.8 to 1.0 point over a period of 2 years in both 
trials. At 2 months, differences in the MiniAQLQ scores between the two treatment 
groups met our definition of equivalence (95% confidence interval [CI] for an ad-
justed mean difference, –0.3 to 0.3). At 2 years, mean MiniAQLQ scores approached 
equivalence, with an adjusted mean difference between treatment groups of –0.11 
(95% CI, –0.35 to 0.13) in the first-line controller therapy trial and of –0.11 (95% CI, 
–0.32 to 0.11) in the add-on therapy trial. Exacerbation rates and ACQ scores did not 
differ significantly between the two groups.
Conclusions
Study results at 2 months suggest that LTRA was equivalent to an inhaled gluco-
corticoid as first-line controller therapy and to LABA as add-on therapy for diverse 
primary care patients. Equivalence was not proved at 2 years. The interpretation of 
results of pragmatic research may be limited by the cross over between treatment 
groups and lack of a placebo group. (Funded by the National Coordinating Centre for 
Health Technology Assessment U.K. and others; Controlled Clinical Trials number, 
ISRCTN99132811.)
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Results of double-blind, random-ized, controlled trials provide, appropri-ately, the bedrock of evidence in determin-
ing the efficacy of therapeutic interventions. Proof 
of efficacy in the trial setting of optimized adher-
ence and follow-up for selective patient popula-
tions does not, however, guarantee that a partic-
ular therapy will be effective in the diverse patient 
populations seen in clinical practice.1-3 In the case 
of asthma, for example, the eligibility criteria in 
most such trials exclude an estimated 95% of pa-
tients with a current diagnosis of asthma, includ-
ing smokers and those who have “insufficient” 
bronchodilator reversibility or impaired pulmonary 
function.4,5 Moreover, the design of such trials 
rarely accounts for the long-term factors that cli-
nicians must consider, such as adherence, inhaler 
technique, tolerability, and physician and patient 
preferences.4-6
Although the results of observational research 
and pragmatic trials can complement those of 
classic randomized, controlled trials, they must 
be interpreted carefully.1,3,7 In particular, the very 
features of pragmatic trials that support the gen-
eralizability, or applicability, of their results to real-
world practice may also reduce assay sensitivity 
and therefore limit the interpretation of results.7,8 
These features include heterogeneous patient pop-
ulations, a lack of blinding, the absence of a pla-
cebo group, and adherence to therapy that is often 
less than optimal.
Asthma treatment guidelines recommend in-
haled glucocorticoids as the first-line controller 
medication for asthma control in patients with 
mild persistent asthma.9,10 These agents have lit-
tle effect on the formation or action of cysteinyl 
leukotrienes, inflammatory mediators in asthma.11 
Leukotriene-receptor antagonists (LTRAs) have 
proved to be beneficial in double-blind, random-
ized, placebo-controlled trials.12-14 Results of prior 
comparisons of LTRA and inhaled glucocorticoids, 
mostly double-blind, randomized, controlled trials, 
have been mixed, with some suggesting that 
LTRAs are less efficacious than inhaled gluco-
corticoids for patients with mild persistent asth-
ma,14-17 and others reporting similar overall asth-
ma control and proportions of patients meeting 
asthma-control criteria.18-20 For patients whose 
symptoms are not controlled with low-dose in-
haled glucocorticoids, step-up therapy consists 
of an increased dose or the addition of LTRA or 
an inhaled long-acting beta2-agonist (LABA).9,10 
Results of randomized clinical trials indicate gen-
erally better improvements in lung function and 
symptoms and a reduction in the need for a short-
acting bronchodilator with step-up therapy con-
sisting of add-on LABA, as compared with add-on 
LTRA.21,22 However, results of long-term trials 
(48 weeks) suggest that clinical outcomes such 
as exacerbations, hospitalizations, and rates of 
emergency treatment are similar with the two 
types of add-on therapy.23
This study, commissioned and predominantly 
funded by the U.K. Health Technology Assessment 
Programme, comprised two separate, 2-year prag-
matic trials designed to evaluate the effective-
ness of LTRA for primary care patients receiving 
asthma therapy under real-world conditions. One 
trial compared LTRA and inhaled glucocorticoids 
for patients in whom asthma-controller therapy 
was being initiated (first-line controller therapy 
trial), and the second compared LTRA and LABA 
as add-on therapy for patients with uncontrolled 
asthma while they were receiving inhaled gluco-
corticoids (add-on therapy trial). We hypothesized 
that initiating treatment with an LTRA or adding 
it to ongoing glucocorticoid therapy would lead to 
clinical improvements in asthma-related quality 
of life, a patient-oriented measure of effective-
ness,9,24,25 that would be equivalent to those with 
the alternative treatment options studied.
Me thods
The study protocol and a detailed description of 
study methods are provided in the Supplementary 
Appendix, available with the full text of this article 
at NEJM.org. The trials were conducted in parallel, 
and the study procedures were similar in the two 
trials. Both trials were conducted in accordance 
with the protocol.
The primary funder and sponsor (National 
Coordinating Centre for Health Technology As-
sessment U.K.) provided input with regard to the 
study design through its commissioning and 
monitoring brief but played no role in data collec-
tion, analysis, or interpretation; the writing of the 
article; or the decision to submit the article for 
publication. The pharmaceutical-industry funders 
had no role in any aspect of the study. Patients 
were responsible for obtaining their own medica-
tions, as would occur in real life.
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Study Patients
The two trials, which were conducted at 53 primary 
care practices in the United Kingdom, enrolled 
patients 12 to 80 years of age with a physician’s 
diagnosis of asthma. In the first-line controller 
therapy trial, eligible patients had asthma symp-
toms deemed by their physician to require initia-
tion of asthma-controller therapy. In the add-on 
therapy trial, eligible patients had received an in-
haled glucocorticoid for at least 12 weeks and 
had symptoms requiring an increase in therapy. 
Other eligibility criteria for both trials included, 
at screening, a peak expiratory flow (PEF) greater 
than 50% of the predicted value after an inhaled 
beta2-agonist had been withheld for 4 hours or 
longer and, at the baseline visit, evidence of im-
paired asthma-related quality of life (a score ≤6 on 
the Mini Asthma Quality of Life Questionnaire25,26 
[MiniAQLQ]) or impaired asthma control (a score 
≥1 on the Asthma Control Questionnaire27 [ACQ]). 
The validated 15-item MiniAQLQ is scored from 
1 to 7, with higher scores indicating less impair-
ment and a minimal clinically important difference 
(MID) of 0.5.25,26 We used a validated, shortened 
version of the ACQ (excluding percent of predicted 
normal forced expiratory volume in one second 
but including short-acting bronchodilator use), on 
which scores range from 0 to 6, with higher scores 
indicating worse asthma control and an MID of 
0.5.27 Main exclusion criteria were prior treatment 
within 12 weeks with an inhaled glucocorticoid or 
LTRA (in the first-line controller therapy trial) or 
LTRA or LABA (in the add-on therapy trial).
The study protocol was reviewed and approved 
by the Eastern Multi Centre Research ethics com-
mittee and local ethics and research governance 
committees. All patients (and parents or guard-
ians of patients under 16 years of age) gave writ-
ten informed consent.
Study Procedures
Patients who met the eligibility criteria completed 
a validated asthma-symptom diary28 for 2 weeks 
before the baseline visit for an assessment of PEF 
variability and to record current symptoms. After 
the screening visit (week –2) and baseline visit 
(week 0), study assessments by telephone or in 
the clinic were scheduled at months 2, 6, 12, 18, 
and 24.
An automated, computerized telephone center 
randomly assigned eligible patients at baseline to 
open-label treatment with either an LTRA (mon-
telukast or zafirlukast) or an inhaled glucocorti-
coid (beclomethasone, budesonide, or fluticasone) 
in the first-line controller therapy trial and with 
either an LTRA or LABA (salmeterol or formoterol) 
together with an inhaled glucocorticoid in the add-
on therapy trial. Randomization was stratified by 
practice, with a block size of 6.
Clinical and lung-function data were recorded 
by clinic staff who were aware of the treatment 
assignments. Data collection and statistical anal-
yses were performed by study personnel who were 
unaware of the treatment assignments; question-
naire-based data were collected under blinded 
conditions, and routine practice data (including a 
history of exacerbations) were extracted with the 
use of dedicated software.
Practice staffs were asked to provide each pa-
tient with a written individualized asthma-action 
plan. For each of the assigned treatments, choices 
of individual drugs and devices were made accord-
ing to normal clinical practice and British asthma 
guidelines.29 The protocol discouraged substan-
tial treatment changes between randomization 
and the 2-month visit. If a patient required a dis-
allowed asthma medication, this fact was noted, 
and the patient remained in the study. Patients 
who withdrew from the study continued to re-
ceive care from their usual clinician.
Outcome Measures
The primary outcome measure was the MiniAQLQ 
score.25,26 Secondary outcome measures included 
the ACQ score27; the score on the not-yet-validated 
Royal College of Physicians 3-item asthma ques-
tionnaire (RCP3) (range of scores, 0 to 3, with 
higher scores indicating worse asthma control)30; 
the score on the validated 14-item Mini Rhino-
conjunctivitis Quality of Life Questionnaire 
(MiniRQLQ) (range of scores, 0 to 6, with higher 
scores indicating worse rhinitis-related impair-
ment and with an MID of 0.7)31; and the frequen-
cy of asthma exacerbations, which were defined as 
the need for an oral course of glucocorticoids or 
hospitalization for asthma.
Statistical Analysis
The primary effectiveness analysis was an inten-
tion-to-treat analysis of the MiniAQLQ score at 
2 months (the primary time point) and at 2 years. 
Analysis of covariance was used, with treatment 
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as a fixed effect and the baseline value as a covari-
ate. A 95% confidence interval (CI) was derived 
for the adjusted difference between mean scores. 
The study was powered for equivalence in the 
MiniAQLQ score, with the equivalence boundary 
set at a 95% CI of less than 0.3 for the MiniAQLQ 
score (i.e., equivalence was declared if the 95% CI 
was wholly included between –0.3 and 0.3). This 
difference reflects our use of an a priori conser-
vative approach (0.3 is substantially lower than the 
MID of 0.5 for the MiniAQLQ26) because of uncer-
tainty about its variability in real-world patients. 
Multiple imputation was used where data were 
missing.32 The same analytic approach was used 
for the ACQ score, although the statistical analysis 
of the ACQ score, as for the other secondary end 
points, was for superiority rather than equivalence.
We determined adherence on the basis of pre-
scriptions issued versus prescribing instructions 
for patients with at least 6 months without a 
change in therapy. We compared median adher-
ence between treatment groups using the Mann–
Whitney test, capping adherence at 100%, since 
adherence exceeded 100% in some cases. We also 
performed four predefined subgroup analyses of 
the MiniAQLQ and ACQ scores at 2 months, com-
paring results according to status with respect to 
smoking (current smokers vs. nonsmokers), base-
line PEF (<80% vs. ≥80% of the predicted value), 
rhinitis versus no rhinitis, and baseline PEF re-
versibility (<15% vs. ≥15%).
We performed a post hoc per-protocol analysis 
of the MiniAQLQ and ACQ scores that included 
patients with data at the relevant time point (i.e., 
2 months or 2 years) who had no change in the 
randomly assigned treatment class and no addi-
tional therapy. The predefined, stricter per-pro-
tocol analysis included patients with no change, 
however minor, in therapy after randomization. 
All analyses were carried out with the use of SAS, 
version 9.1, and SPSS, version 17.0, statistical 
software.
Sample-size calculations were based on pub-
lished results for assessing the effects of treat-
ment differences on the MiniAQLQ score, with a 
between-subject standard deviation of 0.78,25,33 
and were made with the use of nQuery Advisor, 
version 6.0 (Statistical Solutions). A sample of 
178 participants was required for this equiva-
lence study to allow for a 20% dropout rate and 
assuming no true difference between treatments 
in quality of life at a two-tailed alpha level of 
0.05 and with a power of 90% to declare equiva-
lence.
R esult s
Enrollment
Study enrollment is shown in Figures E1 and E2 
in the Supplementary Appendix; additional results 
are detailed in Tables E1 through E28 in the Sup-
plementary Appendix. In both trials, the reason 
for most exclusions after randomization was a 
missing MiniAQLQ or ACQ score or a baseline 
score that was not within the specified range for 
eligibility.
First-Line controller Therapy Trial
Patients
Of 326 patients randomly assigned to a study 
treatment, 20 were excluded after randomization; 
thus, 306 (94%) met all study criteria, and 300 
(92%) were included in the intention-to-treat 
analyses (Fig. E1 in the Supplementary Appendix). 
There were no clinically important differences be-
tween the two treatment groups at baseline (Table 
1). Scores for both the MiniAQLQ and the ACQ 
were available within 3 months before the end of 
the study for 284 of the 300 patients (95%).
Outcome Measures
Mean MiniAQLQ scores in the two treatment 
groups were equivalent at 2 months (Table 2 and 
Fig. 1). At 2 years, the 95% CI for the adjusted dif-
ference in the MiniAQLQ score was outside our 
equivalence limit of 0.3 (Table 2). There were no 
significant differences between treatment groups 
at 2 months or 2 years with respect to the ACQ 
score or any of the other secondary outcome mea-
sures (Tables 2 and 3, and Table E1 in the Supple-
mentary Appendix), including the MiniAQLQ 
domain scores (Table E2 in the Supplementary Ap-
pendix). Rescue bronchodilator use, as reflected in 
patients’ answers to question 6 of the ACQ, fell dur-
ing the study and was similar in both treatment 
groups (Table E3 in the Supplementary Appendix).
At 2 months, 8 of the 145 patients (6%) in the 
LTRA group and 5 of the 155 patients (3%) in 
the inhaled-glucocorticoid group had some mod-
ification in the randomly assigned treatment; at 
2 years, a change in drug class or the addition 
of therapy was recorded for 45 patients (31%) in 
the LTRA group and 32 (21%) in the inhaled-
glucocorticoid group (Table 4). The median rate 
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of adherence to therapy was higher with LTRA 
than with the inhaled glucocorticoid, but not sig-
nificantly so (Table 3).
The post hoc per-protocol results approached 
but did not meet equivalence for the effect on the 
MiniAQLQ score at 2 months and 2 years (Ta-
ble 2). ACQ scores did not differ significantly 
between the LTRA and inhaled-glucocorticoid 
Table 1. Baseline Characteristics of the Patients with Asthma.*
Characteristic First-Line Controller Therapy Trial Add-on Therapy Trial
LTRA
(N = 148)
Inhaled Glucocorticoid 
(N = 158)
LTRA
(N = 170)
LABA
(N = 182)
Mean age — yr 47.6±16.5 44.1±16.4 51.0±16.0 49.7±16.1
Age group — no. of patients (%)
<16 yr 1 (1) 4 (3) 0 0
16–25 yr 17 (12) 17 (11) 12 (7) 17 (9)
26–35 yr 22 (15) 30 (19) 24 (14) 31 (17)
36–45 yr 27 (18) 34 (22) 30 (18) 25 (14)
46–55 yr 30 (20) 33 (21) 32 (19) 39 (21)
56–65 yr 28 (19) 22 (14) 35 (21) 38 (21)
≥66 yr 23 (16) 18 (11) 37 (22) 32 (18)
Female sex — no. of patients (%) 73 (49) 83 (53) 109 (64) 111 (61)
Race — no. of patients (%)†
White 144 (97) 153 (97) 168 (99) 178 (98)
Other or not known 4 (3) 5 (3) 2 (1) 4 (2)
Smoking status — no. of patients/total no. (%)
Current smoker 37/147 (25) 30/155 (19) 29/168 (17) 31/180 (17)
Former smoker 54/147 (37) 54/155 (35) 63/168 (38) 75/180 (42)
Never smoked 56/147 (38) 71/155 (46) 76/168 (45) 74/180 (41)
Current smoker >45 yr of age 15/147 (10) 11/155 (7) 16/168 (10) 16/180 (9)
Peak-expiratory-flow reversibility — % 
(no. of patients tested)
9.2±10.7 (128) 8.7±9.2 (142) 9.0±10.1 (163) 8.3±9.6 (170)
Time since asthma diagnosis — yr
Median 8.5 10 11 11
Interquartile range 3–19 4–16.5 5–22.5 6–21
Assigned therapy — no. of patients/total no. (%)
Montelukast 127/143 (89) 158/166 (95)
Zafirlukast 16/143 (11) 8/166 (5)
Beclomethasone 146/157 (93)
Budesonide 8/157 (5)
Fluticasone 3/157 (2)
Salmeterol 167/181 (92)‡
Formoterol 14/181 (8)‡
Dose of glucocorticoid — μg/day (no. of patients)§ 425±351 (170) 451±390 (182)
* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Patients in the add-on therapy trial were already  
receiving an inhaled glucocorticoid. LABA denotes long-acting beta
2
-agonist, and LTRA leukotriene-receptor antagonist.
† Race was reported by the examiner.
‡ In 18 patients given salmeterol and in 5 patients given formoterol, these drugs were given in fixed-dose combinations with an inhaled gluco-
corticoid.
§ The doses of glucocorticoids were standardized to equivalence with the dose of chlorofluorocarbon–beclomethasone, with doses converted 
as necessary in the following ratios relative to chlorofluorocarbon–beclomethasone: budesonide, 1:1; fluticasone propionate, 2:1; beclo-
methasone in solution, 2:1; and mometasone, 2:1.
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groups (Table E4 in the Supplementary Appen-
dix). In the predefined, stricter per-protocol anal-
ysis (Tables E5 through E8 in the Supplementary 
Appendix), MiniAQLQ scores were better in the 
LTRA group than in the inhaled-glucocorticoid 
group and outside the equivalence limit, with an 
adjusted mean difference of 0.14 (95% CI, –0.15 
to 0.44) at 2 months and 0.05 (95% CI, –0.28 to 
0.37) at 2 years (Table E6 in the Supplementary 
Appendix).
There were no significant differences between 
treatment groups in asthma-diary findings; how-
Table 2. Scores on the MiniAQLQ and ACQ at 2 Months and 2 Years in the Intention-to-Treat and Per-Protocol Populations.*
Outcome Measure Treatment Group
Mean Difference
(95% CI)
Adjusted Mean  
Difference
(95% CI)†
LTRA Inhaled Glucocorticoid
LTRA vs. Inhaled 
Glucocorticoid
LTRA vs. Inhaled 
Glucocorticoid
no. of patients 
tested mean score
no. of patients 
tested mean score
First-line controller therapy trial
ITT MiniAQLQ
At baseline 148 4.75±0.92 158 4.72±0.95
At 2 mo 122 5.25±1.03 132 5.28±1.10 0.00 (−0.25 to 0.26) −0.02 (−0.24 to 0.20)
At 2 yr‡ 145 5.52±1.07 155 5.63±1.16 −0.10 (−0.35 to 0.17) −0.11 (−0.35 to 0.13)
PP MiniAQLQ
At 2 mo 115 5.26±1.02 127 5.35±1.04 −0.09 (−0.35 to 0.18) −0.08 (−0.31 to 0.15)
At 2 yr 98 5.61±1.03 120 5.65±1.16 −0.04 (−0.34 to 0.25) −0.12 (−0.38 to 0.14)
ITT ACQ
At baseline 148 1.99±0.70 158 2.06±0.84
At 2 mo 123 1.54±0.93 132 1.53±1.00 −0.02 (−0.24 to 0.21) 0.01 (−0.20 to 0.22)
At 2 yr‡ 145 1.23±0.95 155 1.15±0.92 0.10 (−0.11 to 0.32) 0.13 (−0.07 to 0.33)
LTRA LABA LTRA vs. LABA LTRA vs. LABA
Add-on therapy trial
ITT MiniAQLQ
At baseline 170 4.63±1.03 182 4.41±1.04
At 2 mo 153 5.09±1.15 156 5.04±1.11 0.06 (−0.18 to 0.30) −0.10 (−0.29 to 0.10)
At 2 yr‡ 169 5.43±1.14 181 5.42±1.08 0.01 (−0.22 to 0.25) −0.11 (−0.32 to 0.11)
PP MiniAQLQ
At 2 mo 147 5.11±1.15 156 5.04±1.11 0.07 (−0.19 to 0.32) −0.09 (−0.29 to 0.11)
At 2 yr 121 5.59±1.04 176 5.44±1.08 0.15 (−0.10 to 0.40) 0.01 (−0.21 to 0.24)
ITT ACQ
At baseline 170 2.01±0.85 182 2.19±0.87
At 2 mo 153 1.62±1.00 156 1.60±0.98 0.01 (−0.20 to 0.22) 0.12 (−0.06 to 0.30)
At 2 yr‡ 169 1.31±0.96 181 1.34±0.92 0.04 (−0.24 to 0.16) 0.04 (−0.15 to 0.22)
* Plus–minus values are means ±SD. In the first-line controller therapy trial, there were 148 patients in the LTRA group and 158 in the 
inhaled-glucocorticoid group at baseline; at 2 months and 2 years, these totals were 145 and 155, respectively. In the add-on therapy trial, 
there were 170 patients in the LTRA group and 182 in the LABA group; at 2 months and 2 years, these totals were 169 and 181, respectively. 
ACQ denotes Asthma Control Questionnaire, CI confidence interval, ITT intention-to-treat, LABA long-acting beta2-agonist, LRTA leukotriene-
receptor antagonist, MiniAQLQ Mini Asthma Quality of Life Questionnaire, and PP per protocol. Scores on the ACQ range from 0 to 6, with 
higher scores representing worse control; scores on the MiniAQLQ range from 1 to 7, with higher scores representing better quality of life. 
The post hoc per-protocol analysis includes patients for whom the randomly assigned treatment was not changed.
† Values have been adjusted for baseline MiniAQLQ or ACQ score.
‡ Multiple imputation was used to impute missing data for the intention-to-treat analyses.
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ever, completion rates were low (Tables E9, E10, 
and E11 in the Supplementary Appendix). There 
was no evidence of differential treatment effects 
on subgroup analyses (Tables E12, E13, and E14 
in the Supplementary Appendix).
One serious reaction occurred during the study 
(an increase in epileptic-seizure frequency) and 
was ascribed by the health care provider to mon-
telukast. The patient discontinued treatment and 
recovered.
Add-On Therapy Trial
Patients
Of 361 patients randomly assigned to treatment 
in the add-on therapy trial, 9 were excluded after 
randomization; thus, 352 (98%) met all study cri-
M
in
iA
Q
LQ
 S
co
re
Best 7
5
3
1
6
4
2
Worst 0
Months
A First-Line Controller Therapy Trial
A
C
Q
 S
co
re
Worst 6
5
3
1
4
2
Best 0
PE
F 
(%
 o
f p
re
di
ct
ed
)
120
100
60
20
80
40
0
0 6 12 18 24
0 6 12 18 24
0 6 12 18 24
B Add-on Therapy Trial
M
in
iA
Q
LQ
 S
co
re
Best 7
5
3
1
6
4
2
Worst 0
Months
A
C
Q
 S
co
re
Worst 6
5
3
1
4
2
Best 0
PE
F 
(%
 o
f p
re
di
ct
ed
)
120
100
60
20
80
40
0
0 6 12 18 24
0 6 12 18 24
0 6 12 18 24
Inhaled corticosteroid LTRA LTRALABA
Figure 1. Time Course of Improvements in ACQ and MiniAQLQ Scores and Peak Expiratory Flow over a 2-Year Period 
in Patients with Asthma.
Panel A shows outcomes over a 2-year period for patients receiving a leukotriene-receptor antagonist (LTRA) or an 
inhaled glucocorticoid as first-line asthma-controller therapy. Panel B shows outcomes over a 2-year period for pa-
tients receiving an LTRA or a long-acting beta2-agonist (LABA) as an add-on to an inhaled glucocorticoid. ACQ de-
notes Asthma Control Questionnaire (on which scores [shown as means ±SD] range from 0 to 6, with higher scores 
representing worse control and a minimal clinically important difference [MID] of 0.5), MiniAQLQ Mini Asthma 
Quality of Life Questionnaire (on which scores [shown as means ±SD] range from 1 to 7, with higher scores repre-
senting better quality of life and an MID of 0.5), and PEF peak expiratory flow (shown as medians with I bars repre-
senting the interquartile ranges).
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teria, and 350 (97%) patients were included in the 
intention-to-treat analyses (Fig. E2 in the Supple-
mentary Appendix). There were no clinically im-
portant differences between treatment groups at 
baseline (Table 1). Both the MiniAQLQ and ACQ 
scores were available within 3 months before the 
study end for 337 of 350 (96%) patients.
Outcome Measures
Mean MiniAQLQ scores in the two treatment 
groups were equivalent at 2 months, whereas at 
2 years, the adjusted 95% CI for the difference 
in the MiniAQLQ scores was just outside the 
equivalence limit of 0.3 (Table 2 and Fig. 1). The 
MiniAQLQ domain scores are summarized in Ta-
ble E15 in the Supplementary Appendix.
The mean ACQ score did not differ signifi-
cantly between the treatment groups (Table 2 
and Fig. 1). Of the 337 patients for whom long-
term data on ACQ scores were available, 80 of 162 
(49%) in the LTRA group and 77 of 175 (44%) in 
the LABA group had controlled asthma as de-
Table 3. Secondary Outcome Measures.*
Outcome Measure Treatment Group
Rate Ratio 
(95% CI)† P Value
LTRA  
(N = 148)
Inhaled Glucocorticoid  
(N = 158)
LTRA vs. Inhaled 
Glucocorticoid
First-line controller therapy trial
Asthma exacerbations
Any — no. of exacerbations 0.44±0.94 0.35±0.95 1.27 (0.83–1.92) 0.23
1 — no. of patients/total no. (%) 19/148 (13) 13/158 (8)
>1 — no. of patients/total no. (%) 17/148 (11) 14/158 (9)
Adherence
No. of patients 108 101
Rate — % 0.11
Median 65 41
Interquartile range 15–92 21–62
LTRA (N = 170) LABA (N = 182) LTRA vs. LABA
Add-on therapy trial
Asthma exacerbations
Any — no. of exacerbations 0.62±1.13 0.61±1.03 1.02 (0.74–1.41) 0.90
1 — no. of patients/total no. (%) 32/170 (19) 41/182 (23)
>1 — no. of patients/total no. (%) 26/170 (15) 25/182 (14)
Adherence
No. of patients 136 142
Rate — % 0.007
Median 74 46
Interquartile range 14–100 16–73
Adherence to inhaled glucocorticoid
No. of patients 103 128
Rate — % 0.26
Median 76 64
Interquartile range 27–100 34–91
* Plus–minus values are means ±SD. P values are for the comparison between treatment groups (with the use of the 
Wald chi-square test from the Poisson model for exacerbations and the Mann-Whitney test for adherence). LABA 
 denotes long-acting beta2-agonist, and LTRA leukotriene-receptor antagonist.
† Rate ratios were obtained with the use of the Poisson model, with treatment group as the sole explanatory variable.
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fined by a final ACQ score of 1.0 or lower.34 
Results for the other secondary outcome mea-
sures were similar in the two groups (Table 3, 
and Table E16 in the Supplementary Appendix), 
with the exception of the MiniRQLQ score, which 
was significantly better at 2 months but not at 
2 years for patients receiving LTRA (Table E16 in 
the Supplementary Appendix). Rescue bronchodi-
lator use, recorded on the basis of the response to 
question 6 of the ACQ, fell during the study and 
was similar in the two treatment groups (Table 
E3 in the Supplementary Appendix).
One fourth of the patients in the LTRA group 
were switched to LABA or received add-on LABA, 
whereas there were no changes in the prescribed 
drug class for the LABA group over the 2 years of 
the trial (Table 4). Median adherence to therapy 
was significantly better with LTRA than with 
LABA (Table 3).
Post hoc per-protocol results for the MiniAQLQ 
score were equivalent in the two treatment groups 
at 2 months and 2 years (Table 2). The ACQ scores 
did not differ significantly between the LTRA 
and LABA groups (Table E17 in the Supplemen-
tary Appendix). In the predefined, stricter per-
protocol analysis (Tables E18 through E21 in the 
Supplementary Appendix), the difference in the 
MiniAQLQ scores was outside the equivalence 
limit, with an adjusted mean difference of −0.02 
(95% CI, −0.36 to 0.31) at 2 months and −0.05 
(95% CI, −0.36 to 0.26) at 2 years (Table E19 in 
the Supplementary Appendix).
On asthma-diary cards, daytime and nighttime 
use of short-acting bronchodilators was signifi-
cantly greater in the LTRA group than in the 
LABA group at 2 months but not at 2 years; card-
completion rates were about 65% at 2 months 
and 50% at 2 years (Tables E22, E23, and E24 in 
the Supplementary Appendix). There was no evi-
dence of differential treatment effects in subgroup 
analyses (Tables E25, E26, and E27 in the Supple-
mentary Appendix).
Discussion
Mean improvements over a period of 2 years in 
both the first-line controller and the add-on ther-
apy trials were substantially greater than the MID 
for questionnaire scores measuring asthma-related 
quality of life and asthma control. For patients re-
ceiving an LTRA or an inhaled glucocorticoid as 
first-line controller therapy, MiniAQLQ scores were 
Table 4. Changes in Treatment According to the Assigned Treatment.*
Treatment Change
No. of patients 
(%)
LTRA, first-line controller therapy trial
Total in group 145
Changes at 2 mo
Crossed over to inhaled glucocorticoid 6
Crossed over to inhaled glucocorticoid plus LABA 1
Had multiple changes 1
Total 8 (5.5)
Changes at 2 yr
Added inhaled glucocorticoid 4
Added inhaled glucocorticoid and LABA 2
Crossed over to inhaled glucocorticoid 27
Crossed over to inhaled glucocorticoid and LABA 8
Crossed over to inhaled glucocorticoid, then added LABA 3
Had multiple changes 1
Total 45 (31.0)
Inhaled glucocorticoid, first-line controller therapy trial
Total in group 155
Changes at 2 mo
Added LABA 3
Crossed over to LTRA 2
Total 5 (3.2)
Changes at 2 yr
Added LABA 28
Crossed over to LTRA 4
Total 32 (20.6)
LTRA, add-on therapy trial
Total in group 169
Changes at 2 mo
Crossed over to LABA 6
Added LABA 1
Total 7 (4.1)
Changes at 2 yr
Crossed over to LABA 25
Added LABA 18
Total 43 (25.4)
LABA, add-on therapy trial
Total in group 181
Changes at 2 mo None
Changes at 2 yr None
* LABA denotes long-acting beta2-agonist, and LTRA leukotriene-receptor antagonist.
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equivalent at 2 months, but at 2 years, these scores 
did not meet our prespecified criterion for equiv-
alence, since the lower boundary of the 95% CI 
was –0.35. Similarly, for patients receiving add-on 
therapy with an LTRA or LABA, MiniAQLQ scores 
were equivalent at 2 months but not at 2 years 
(lower boundary of 95% CI, –0.32). Our equiva-
lence boundary of 0.30 was chosen to be conserva-
tive, within the 0.5 MID for the MiniAQLQ score.26 
In both trials, secondary outcome measures were 
similar in the two treatment groups, including 
asthma control as measured by the ACQ score and 
the frequency of asthma exacerbations, RCP3 score, 
and clinic-measured PEF.
Although our findings suggest that there is 
little difference in real-world effectiveness between 
an LTRA and an inhaled glucocorticoid as first-
line controller therapy and between an LTRA and 
a LABA as an add-on to an inhaled glucocorti-
coid, caution is needed in interpreting the results 
of these pragmatic trials. As noted by Temple and 
Ellenberg,8 active-control trials may have limited 
assay sensitivity. Moreover, study characteristics 
that tend to reduce observable differences between 
treatments, including nonadherence, use of con-
comitant therapy that could affect outcomes, and 
enrollment of patients who do not have the dis-
ease or who have spontaneous improvement, could 
all be operative in the present study. Specifically, 
the lack of a placebo-control group limits the 
ascertainment of effectiveness, and open-label 
treatment assignments, differential adherence, 
crossover between treatment groups, and the (in-
tentional) enrollment of a heterogeneous real-
world patient population could bias the results 
toward equivalence.
We considered but rejected the addition of a 
placebo group when designing the study, since 
we believe it would have been unethical to assign 
patients to placebo for 2 years. All enrolled pa-
tients had evidence of asthma-related impair-
ment on the ACQ, the MiniAQLQ, or both and 
were considered by their physicians to need regu-
lar therapy for their asthma after a 2-week run-in 
period. In contrast, other long-term studies of 
asthma therapy that included a placebo group 
either enrolled patients with mild asthma35 or 
excluded patients if a delay in inhaled glucocor-
ticoid therapy was judged by physicians to be 
inappropriate.36
Double-blind treatment, although ideal for in-
ternal validity, would have severely affected the 
external validity (applicability) of this study. First, 
not revealing treatment assignments to the pa-
tients and health care providers would have ham-
pered our goal of assessing the effect of differ-
ential adherence to oral versus inhaled therapy 
under conditions of usual patient and physician 
behaviors and preferences. Second, it would not 
have been possible to charge typical prescribing 
costs, which might have affected adherence. Bias 
due to the lack of blinding would probably have 
favored prescription of an inhaled glucocorticoid 
and an add-on LABA because of clear position-
ing in U.K. guidelines regarding the use of these 
medications.
Adherence to an LTRA was better than it was 
to the other drugs in both trials, with adherence 
rates that were numerically higher in the first-
line controller therapy trial (65%, vs. 41% for an 
inhaled glucocorticoid) and significantly higher 
in the add-on therapy trial (74%, vs. 46% for a 
LABA). Although such poor and differential ad-
herence potentially reduces assay sensitivity (par-
ticularly when coupled with treatment crossover), 
thus biasing results toward equivalence, both poor 
and differential adherence rates are realities of 
real-world prescribing6 and thus part of the 
treatment effect. It is reassuring that the results at 
2 months were similar to those at 2 years, since 
the 2-month time point represents a standard ef-
ficacy period with high adherence and minimal 
contamination associated with treatment changes. 
The 2-year time point better reflects the real-world 
effectiveness of the therapy chosen initially.
The crossover between treatment groups was 
regrettable but unavoidable, since this was a prag-
matic trial and we allowed usual practice to occur. 
Treatment changes were made for more patients 
in the LTRA groups in both trials. This meant 
that, although the per-protocol results generally 
supported the findings in the intention-to-treat 
analysis, proportionately fewer LTRA-treated pa-
tients were included in the per-protocol popula-
tions.
We cannot rule out treatment failure as a 
reason for disparities in crossover. However, be-
cause LTRAs are not commonly prescribed in 
the United Kingdom as first-line or add-on anti-
inflammatory therapy, or not recommended as 
such by U.K. guidelines, it is possible that pa-
tients in the LTRA groups, on being reviewed by a 
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clinician unfamiliar with the study, were switched 
to an inhaled glucocorticoid or add-on LABA 
according to normal practice protocol.10,29 Since 
7 to 10 physicians work in the typical U.K. gen-
eral practice, it was difficult for us to keep all 
physicians apprised of the study goals and the 
need to maintain the study therapies. Finally, in 
the case of treatment failure, there was no room 
for change within the treatment class for the 
LTRA groups, whereas the inhaled glucocorti-
coid could be changed or the dose could be in-
creased.
Impairment of lung function among our en-
rolled patients was milder than that of patients 
in many randomized clinical trials because a 
forced expiratory volume in 1 second of less 
than 80% of the predicted value or 15% revers-
ibility was not required for eligibility. Since there 
was less room for improvement in PEF values, 
this measurement had poor sensitivity. However, 
there was considerable room for improvement 
in other measurements, and in all treatment 
groups, substantial improvements were recorded 
in asthma-related quality of life (an unadjusted 
mean increase from baseline of 0.8 to 1.0 in the 
MiniAQLQ score) and asthma control (a mean 
decrease of 0.7 to 0.9 in the ACQ score).
The limitations of these active-control equiva-
lence trials are difficult to quantitate.8 Com-
parisons with other studies are problematic be-
cause of differences in study design and patient 
populations; however, the baseline values and 
outcomes in our studies are crudely similar to 
those in the Gaining Optimal Asthma Control 
(GOAL) study37 and the Formoterol and Cortico-
steroids Establishing Therapy (FACET) study,38 
and the outcomes in our study are better than 
those in the placebo group of the Optimal Man-
agement of Asthma (OPTIMA) study35 (see Table 
E28 in the Supplementary Appendix). Nonethe-
less, we cannot rule out regression to the mean, 
and study results could simply be a reflection of 
the inherent variability of asthma, since patients 
may have been recruited at a time when their 
asthma was unstable.
The ACQ score and exacerbation frequency 
are two key markers of asthma control recog-
nized by international consensus.24 There were 
no significant differences between treatment 
groups in these measures for intention-to-treat or 
per-protocol population in either trial, although 
exacerbations were infrequent overall. Data for 
asthma-related quality of life and asthma control 
were available over a period of 21 months for 95% 
and 96% of the patients in the first-line control-
ler and add-on therapy trials, respectively, which 
are completion rates higher than those in most 
long-term asthma-therapy trials.35,37,39
We designed these two pragmatic trials7 to 
maximize external validity (applicability or gen-
eralizability), with the goal of studying a hetero-
geneous real-world population. Although this 
approach limits the efficacy assessment, we be-
lieve it has the advantage of exploring a question 
that cannot be answered in more tightly con-
trolled, randomized, controlled trials — namely, 
what is the real-world effectiveness of these prov-
en therapies for the heterogeneous population of 
patients seen in practice, including those who 
smoke and those with coexisting conditions, 
poor adherence, or poor inhaler technique? Ac-
tive smokers are typically excluded from clinical 
trials, but such patients accounted for almost one 
fourth of our study population, with smokers 
over 45 years of age representing about 9% of 
patients in both trials. Because we did not require 
evidence of bronchodilator reversibility, enrolled 
patients may have had a combination of chronic 
obstructive pulmonary disease (COPD) and asth-
ma. We estimate that 3% of the study population 
had some degree of COPD, since reportedly, 25% 
of smokers over 40 years of age who are treated 
for asthma in clinical practice have COPD.40 
Nonetheless, verification of the asthma diagnosis 
with spirometry would have been ideal, and there 
is clearly a need for better diagnostic standards in 
primary care.
Although our eligibility criteria allowed for 
patients as young as 12 years old to be included, 
few patients were younger than 25 years of age; 
thus, our findings apply only to adults. The stan-
dard deviation used in the power calculation is 
smaller than the observed standard deviation in 
our data, and we attribute this difference to the 
greater heterogeneity of our study population as 
compared with populations in previously re-
ported studies33 — a factor that should be con-
sidered in future pragmatic trials.
The results of these two pragmatic trials sug-
gest that an LTRA is equivalent to both compari-
son drugs with regard to the effect on asthma-
related quality of life at 2 months in a diverse 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 364;18 nejm.org may 5, 20111706
patient population with asthma. Equivalence was 
not proved at 2 years. Although the quality-of-
life results, taken together with asthma control 
and other outcome measures, show little differ-
ence in clinical effectiveness between an LTRA 
and an inhaled glucocorticoid as first-line con-
troller therapy and between an LTRA and a LABA 
as an add-on to an inhaled glucocorticoid, it is 
important to recognize that features of these 
pragmatic trials could produce a bias toward 
equivalence. Nonetheless, our findings suggest 
that caution should be applied in extrapolating 
results from randomized clinical trials to the 
broad population of patients with asthma who 
are treated in community settings. Clinical deci-
sion making can best be guided by viewing the 
results of conventional randomized, controlled 
trials in conjunction with the results of prag-
matic trials.
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